Abbott will spearhead an initiative to help increase diversity in clinical trials through boosting access, funding scholarships and uniting leaders on an advisory board, the company announced today. Morningstar: Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month ... Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 FiercePharma: Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting Abbott creates innovative medical devices and healthcare solutions for cardiovascular health, diabetes management, diagnostic …

General Overview

Clinical Trials Arena on MSN: ESC 2026: Abbott presents positive longer-term dual ablation catheter data TCTMD: Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent Abbott Park, Illinois — Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb ... Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s coronary intravascular lithotripsy (IVL) system in a clinical trial. The ... For a more comprehensive perspective, our dedicated coverage of Food Lion Georgia Locations offers a detailed breakdown on this subject.